Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pesticide Exposure and Parkinson's Disease: A Qualitative Study of Experiences in Ireland.

Health expectations : an international journal of public participation in health care and health policy·2025
Same author

The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in in vitro and in vivo 6-hydroxydopamine models of Parkinson's disease.

Neuropharmacology·2025
Same author

Alpha-synuclein-induced upregulation of SKI family transcriptional corepressor 1: A new player in aging and Parkinson's disease?

Neural regeneration research·2024
Same author

Impacts of gait freeze on quality of life in Parkinson's disease, from the perspectives of patients and their carers.

Irish journal of medical science·2024
Same author

Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.

Aging cell·2024
Same author

Assessment of an online tooth morphology course and 3D examination tool during the COVID-19 pandemic.

European journal of dental education : official journal of the Association for Dental Education in Europe·2024

Related Experiment Video

Updated: Jul 4, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Progress in Parkinson's disease-where do we stand?

André Toulouse1, Aideen M Sullivan

  • 1Department of Anatomy/Neuroscience and Biosciences Institute, University College Cork, Cork, Ireland. a.toulouse@ucc.ie

Progress in Neurobiology
|June 28, 2008
PubMed
Summary

Parkinson's disease management has improved, but halting progression remains elusive. Recent advances in neuroprotection and cell replacement offer hope for future Parkinson's disease therapies.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Parkinson's disease is a common neurodegenerative disorder affecting movement control via nigrostriatal pathways.
  • Current treatments like L-DOPA manage symptoms but do not halt disease progression or restore function.
  • Understanding neurodegeneration and neuronal development has spurred new therapeutic strategies.

Purpose of the Study:

  • To review current knowledge on Parkinson's disease etiology.
  • To discuss existing symptomatic treatments for Parkinson's disease.
  • To explore recent advancements in neuroprotective and cell replacement therapies for Parkinson's disease.

Main Methods:

  • Literature review of Parkinson's disease research.
  • Analysis of current therapeutic modalities.
  • Examination of preclinical and early-stage clinical trial data for novel therapies.

Main Results:

  • Significant progress in understanding Parkinson's disease pathogenesis over the last decade.
  • Development of novel pharmaceutical compounds with demonstrated neuroprotective properties.
  • Emerging potential of cell replacement therapies, though clinical translation faces challenges.

Conclusions:

  • While current Parkinson's disease therapies are primarily symptomatic, new approaches show promise.
  • Neuroprotective and cell replacement strategies represent the future direction for Parkinson's disease treatment.
  • Continued research is crucial for overcoming obstacles to clinical implementation of advanced therapies.